{
 "as_of": "2026-11-08",
 "cmr": "us-cm-kg/NASDAQ/GTBP",
 "fence": "The page is the record's research on the issuer — no analyst, no rating, no view.",
 "markdown": "The page is the record's research on the issuer — no analyst, no rating, no view.\n\n# GT Biopharma, Inc. (NASDAQ: GTBP) — research page\n\nAs of 2026-11-08 · us-cm-kg · record version 1\n\n## Identity and listing\n\nThe issuer is GT Biopharma, Inc., listed on NASDAQ under the ticker GTBP. The ISIN is not on the record and the LEI is not on the record. The security type is Corporate, the sector is 2834 Pharmaceutical Preparations, and the jurisdiction is the United States, Delaware. The segment is not on the record. The listing status is listed, not halted.\n\n## The disclosure read\n\nThe record holds 40 filings across 30 filing days in the window 2025-11-08 to 2026-11-08. Of these, 11 are regulatory filings, 8 are prospectuses, 7 are results, 5 are AGM or EGM filings, 5 are corporate news, 2 are ad hoc, and 2 are halt or suspension filings. The median gap between filing days is 6 days. The latest filing is dated 2026-10-20 and is of type regulatory_filing, 19 days before the record date. On NASDAQ the median filings are 52, the median cadence gap is 6.0 days, and the median latency is 5.0 days. On the sector 2834 Pharmaceutical Preparations the median filings are 63.0, the median cadence gap is 6.0 days, and the median latency is 4.0 days.\n\n## Auditor\n\nThe auditor of record is Weinberg & Company, P.A., located in Los Angeles, California. The record holds no auditor changes.\n\n## Events and halts\n\nThe record holds no listing, delisting or name change lines. The domicile change is not on the record, because EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, because the exchanges' tier transfers are not EDGAR filings. The halt flag reads listed, not halted.\n\n## Orderability\n\nThe outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.\n\n## Coverage\n\nOne research house is named on the issuer's own investor-relations page: Roth Capital Partners.\n\n## Open research\n\nNo openly published research notes were found on the record.\n\n## Licensed\n\nLicensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.\n\n## As-of depth\n\nThe record holds sealed years 2021, 2022, 2023, 2024, 2025 and 2026 for the issuer. The market's earliest sealed date is 2021-01-04, and the live record began on 2026-09-12.\n\n## Sources\n\n8 source pages are named on this page; every value above carries its own source page and read date in the numbers.\n\n- https://www.sec.gov/files/company_tickers_exchange.json (identity.exchange)\n- https://data.sec.gov/submissions/CIK0000109657.json (identity.jurisdiction)\n- https://mcp.us-cm-kg.ai/events/NASDAQ/GTBP (the disclosure lines)\n- https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts (the halt flag)\n- https://www.sec.gov/Archives/edgar/data/109657/000149315226008443/form10-k.htm (the auditor)\n- https://mcp.us-cm-kg.ai/book/aio.json (the orderability chapter)\n- https://ir.gtbiopharma.com/analyst-coverage (coverage)\n- https://mcp.us-cm-kg.ai/record/NASDAQ/GTBP (the record)\n",
 "market": "US",
 "node": "us-cm-kg",
 "numbers": {
  "as_of_depth": {
   "issuer_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "live_record_began": "2026-09-12",
   "node_history_from": "2021-01-04",
   "node_years_sealed": [
    "2021",
    "2022",
    "2023",
    "2024",
    "2025",
    "2026"
   ],
   "record_version": 1,
   "sealed": true
  },
  "auditor": {
   "auditor": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/109657/000149315226008443/form10-k.htm",
    "state": "sourced",
    "value": "Weinberg & Company, P.A"
   },
   "auditor_firm_id": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/109657/000149315226008443/form10-k.htm",
    "state": "sourced",
    "value": "572"
   },
   "auditor_location": {
    "read_by": "EDGAR 10-K cover page iXBRL tag (dei:AuditorName, dei:AuditorLocation, dei:AuditorFirmId, dei:DocumentPeriodEndDate)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/Archives/edgar/data/109657/000149315226008443/form10-k.htm",
    "state": "sourced",
    "value": "Los Angeles, California"
   },
   "changes": []
  },
  "cmr": "us-cm-kg/NASDAQ/GTBP",
  "coverage": {
   "count": 1,
   "houses": [
    {
     "analyst": "Jonathan Aschoff, Ph.D.",
     "house": "Roth Capital Partners",
     "read_by": "issuer IR page, fetched by this rail; each house name read on the page",
     "read_date": "2026-11-11",
     "source": "https://ir.gtbiopharma.com/analyst-coverage",
     "state": "sourced"
    }
   ],
   "pages_checked": [
    {
     "page": "https://ir.gtbiopharma.com/analyst-coverage",
     "result": "read: 1 of 2 named houses found on the page"
    }
   ],
   "read_by": "Perplexity sonar (search) · page read by this rail",
   "read_date": "2026-11-11",
   "since": "not stated on the page read",
   "state": "found"
  },
  "disclosure": {
   "against": {
    "exchange": {
     "issuers": 4359,
     "median_cadence_gap_days": 6,
     "median_filings": 52,
     "median_latency_days": 5,
     "name": "NASDAQ"
    },
    "sector": {
     "issuers": 526,
     "median_cadence_gap_days": 6,
     "median_filings": 63,
     "median_latency_days": 4,
     "name": "2834 Pharmaceutical Preparations"
    }
   },
   "by_type": {
    "ad_hoc": 2,
    "agm_egm": 5,
    "corporate_news": 5,
    "halt_suspension": 2,
    "prospectus": 8,
    "regulatory_filing": 11,
    "results": 7
   },
   "cadence_median_gap_days": 6,
   "filing_days": 30,
   "filings": 40,
   "latency_days": 19,
   "latest": [
    {
     "category": "EFFECT",
     "date": "2026-10-20",
     "source": "https://www.sec.gov/Archives/edgar/data/109657/999999999526003305/xslEFFECTX01/primary_doc.xml",
     "title": "EFFECT (items ,,)",
     "type": "regulatory_filing"
    },
    {
     "category": "424B3",
     "date": "2026-10-20",
     "source": "https://www.sec.gov/Archives/edgar/data/109657/000149315226047792/form424b3.htm",
     "title": "424B3 — 424B3",
     "type": "prospectus"
    },
    {
     "category": "DEF 14A",
     "date": "2026-10-13",
     "source": "https://www.sec.gov/Archives/edgar/data/109657/000149315226046861/formdef14a.htm",
     "title": "DEF 14A — DEF 14A",
     "type": "agm_egm"
    },
    {
     "category": "S-1",
     "date": "2026-10-09",
     "source": "https://www.sec.gov/Archives/edgar/data/109657/000149315226046618/forms-1.htm",
     "title": "S-1 — S-1",
     "type": "prospectus"
    },
    {
     "category": "PRE 14A",
     "date": "2026-10-02",
     "source": "https://www.sec.gov/Archives/edgar/data/109657/000149315226045611/formpre14a.htm",
     "title": "PRE 14A — PRE 14A",
     "type": "agm_egm"
    }
   ],
   "latest_filing_date": "2026-10-20",
   "read": "the node's event lines (list_events_since), as get_filings serves them",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/GTBP",
   "window": {
    "from": "2025-11-08",
    "to": "2026-11-08"
   }
  },
  "identity": {
   "exchange": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "NASDAQ"
   },
   "isin": {
    "market": "US",
    "reason": "no LEI, so no GLEIF ISIN route; EDGAR carries no ISIN",
    "state": "not_on_record"
   },
   "jurisdiction": {
    "read_by": "EDGAR submissions API (issuer header as filed) (stateOfIncorporation)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0000109657.json",
    "state": "sourced",
    "value": "United States — Delaware"
   },
   "lei": {
    "market": "US",
    "reason": "no GLEIF record with the exact legal name in jurisdiction US-DE",
    "state": "not_on_record"
   },
   "name": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0000109657.json",
    "state": "sourced",
    "value": "GT Biopharma, Inc."
   },
   "sector": {
    "read_by": "EDGAR submissions API (issuer header as filed) (SIC code as assigned by the SEC)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0000109657.json",
    "state": "sourced",
    "value": "2834 Pharmaceutical Preparations"
   },
   "security_type": {
    "read_by": "EDGAR submissions API (issuer header as filed)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://data.sec.gov/submissions/CIK0000109657.json",
    "state": "sourced",
    "value": "Corporate"
   },
   "segment": {
    "market": "US",
    "state": "not_on_record"
   },
   "ticker": {
    "read_by": "EDGAR company_tickers_exchange.json (SEC list of exchange-listed filers)",
    "read_date": "2026-11-08",
    "read_date_basis": "the record version as_of",
    "source": "https://www.sec.gov/files/company_tickers_exchange.json",
    "state": "sourced",
    "value": "GTBP"
   },
   "website": {
    "market": "US",
    "state": "not_on_record"
   }
  },
  "licensed": {
   "columns": [
    "licensor",
    "entitlement",
    "title",
    "date",
    "source"
   ],
   "rows": [],
   "rule": "A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded."
  },
  "lifecycle": {
   "delisting": [],
   "domicile_change": {
    "market": "US",
    "reason": "EDGAR states no dated change of state of incorporation on a filing line",
    "state": "not_on_record"
   },
   "listing": [],
   "name_change": [],
   "segment_move": {
    "market": "US",
    "reason": "the exchanges' tier transfers are not EDGAR filings",
    "state": "not_on_record"
   }
  },
  "market": "US",
  "node": "us-cm-kg",
  "numbers_hash": "sha256:073e57b10525d790d7d0bfa93c59d897e97278d6f4bae91ee244763b29f235fd",
  "open_research": {
   "read_date": "2026-11-11",
   "rows": [],
   "state": "none_found"
  },
  "orderability": {
   "chapter_as_of": "2026-11-04",
   "client_categories": [],
   "determinable": false,
   "read": {
    "chapter": "https://mcp.us-cm-kg.ai/book/aio.json",
    "door": "https://mcp.us-cm-kg.ai/mcp",
    "tool": "get_orderability"
   },
   "reason": "the chapter's orderability section carries no client_categories: the outcome cannot name its client category",
   "rule_version": "acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1",
   "section": "us.aio.v8"
  },
  "record": {
   "as_of": "2026-11-08",
   "url": "https://mcp.us-cm-kg.ai/record/NASDAQ/GTBP",
   "version": 1
  },
  "schema": "research-numbers v0.1 (USR-01, 2026-11-11)",
  "status": {
   "read_date": "2026-11-08",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts",
   "value": "listed, not halted"
  }
 },
 "numbers_hash": "sha256:073e57b10525d790d7d0bfa93c59d897e97278d6f4bae91ee244763b29f235fd",
 "path": "/us/NASDAQ/GTBP",
 "schema": "research-page v0.1 (USR-02, 2026-11-11)",
 "sections": [
  {
   "id": "identity",
   "text": "The issuer is GT Biopharma, Inc., listed on NASDAQ under the ticker GTBP. The ISIN is not on the record and the LEI is not on the record. The security type is Corporate, the sector is 2834 Pharmaceutical Preparations, and the jurisdiction is the United States, Delaware. The segment is not on the record. The listing status is listed, not halted.",
   "title": "Identity and listing"
  },
  {
   "id": "disclosure",
   "text": "The record holds 40 filings across 30 filing days in the window 2025-11-08 to 2026-11-08. Of these, 11 are regulatory filings, 8 are prospectuses, 7 are results, 5 are AGM or EGM filings, 5 are corporate news, 2 are ad hoc, and 2 are halt or suspension filings. The median gap between filing days is 6 days. The latest filing is dated 2026-10-20 and is of type regulatory_filing, 19 days before the record date. On NASDAQ the median filings are 52, the median cadence gap is 6.0 days, and the median latency is 5.0 days. On the sector 2834 Pharmaceutical Preparations the median filings are 63.0, the median cadence gap is 6.0 days, and the median latency is 4.0 days.",
   "title": "The disclosure read"
  },
  {
   "id": "auditor",
   "text": "The auditor of record is Weinberg & Company, P.A., located in Los Angeles, California. The record holds no auditor changes.",
   "title": "Auditor"
  },
  {
   "id": "events",
   "text": "The record holds no listing, delisting or name change lines. The domicile change is not on the record, because EDGAR states no dated change of state of incorporation on a filing line. The segment move is not on the record, because the exchanges' tier transfers are not EDGAR filings. The halt flag reads listed, not halted.",
   "title": "Events and halts"
  },
  {
   "id": "orderability",
   "text": "The outcome is not determinable. The chapter's orderability section carries no client categories, so the outcome cannot name its client category. The rule version is acm-68000/us/reasonable-basis-suitability-finra-rule-2111/r1, and the chapter is as of 2026-11-04.",
   "title": "Orderability"
  },
  {
   "id": "coverage",
   "text": "One research house is named on the issuer's own investor-relations page: Roth Capital Partners.",
   "title": "Coverage"
  },
  {
   "id": "open_research",
   "text": "No openly published research notes were found on the record.",
   "title": "Open research"
  },
  {
   "id": "licensed",
   "text": "Licensed research: none loaded. A licensed row is served only to an agent whose firm holds that licence (licensor, entitlement). No licensed row is loaded.",
   "title": "Licensed"
  },
  {
   "id": "depth",
   "text": "The record holds sealed years 2021, 2022, 2023, 2024, 2025 and 2026 for the issuer. The market's earliest sealed date is 2021-01-04, and the live record began on 2026-09-12.",
   "title": "As-of depth"
  },
  {
   "id": "sources",
   "text": "8 source pages are named on this page; every value above carries its own source page and read date in the numbers.",
   "title": "Sources"
  }
 ],
 "sources": [
  {
   "for": "identity.exchange",
   "source": "https://www.sec.gov/files/company_tickers_exchange.json"
  },
  {
   "for": "identity.jurisdiction",
   "source": "https://data.sec.gov/submissions/CIK0000109657.json"
  },
  {
   "for": "the disclosure lines",
   "source": "https://mcp.us-cm-kg.ai/events/NASDAQ/GTBP"
  },
  {
   "for": "the halt flag",
   "source": "https://www.nasdaqtrader.com/rss.aspx?feed=tradehalts"
  },
  {
   "for": "the auditor",
   "source": "https://www.sec.gov/Archives/edgar/data/109657/000149315226008443/form10-k.htm"
  },
  {
   "for": "the orderability chapter",
   "source": "https://mcp.us-cm-kg.ai/book/aio.json"
  },
  {
   "for": "coverage",
   "source": "https://ir.gtbiopharma.com/analyst-coverage"
  },
  {
   "for": "the record",
   "source": "https://mcp.us-cm-kg.ai/record/NASDAQ/GTBP"
  }
 ],
 "title": "GT Biopharma, Inc. (GTBP) — research page",
 "writer": {
  "by": "Claude through the platform account, Haiku class; one pass; checked against the numbers",
  "engine": "claude-haiku-5-5"
 }
}